Big Ideas 2026: Multiomics

Key Concepts

• Multiomics: A systems-level biological approach integrating data from five core layers: Genomics (DNA), Epigenomics (gene regulation), Transcriptomics (RNA), Proteomics (proteins), and Metabolomics (small molecules).
• AI Flywheel: The reinforcing cycle where increased biological data improves AI models, which in turn create better diagnostics and therapeutics, generating even more data.
• Functional Cures: Therapies that durably eliminate disease activity after a limited course of treatment, moving away from the chronic care model.
• In Vivo Gene Editing: Editing genes directly within the patient's body to treat conditions like cardiovascular disease.
• Quality-Adjusted Life Years (QALYs): A health economics metric used to measure the value of life extension and quality improvements.

1. The Multiomics Framework and Data Generation

Multiomics shifts biological research from isolated layers to a holistic, systems-level view. Innovation is occurring simultaneously across the biological stack, creating a "virtuous cycle" driven by AI.

• Data Growth: The cost of sequencing a whole human genome has plummeted from $2.7 billion (Human Genome Project) to ~$100 today, with projections to reach ~$10 by 2030.
• Data Volume: Molecular diagnostic tests are generating data volumes that rival the training sets of frontier Large Language Models (LLMs). This volume is expected to scale 10-fold by 2030.

2. AI-Enabled Diagnostics and Drug Development

AI is fundamentally altering the economics of healthcare by increasing precision and reducing development timelines.

• Diagnostics: Since late 2022, there has been a significant inflection in FDA approvals for AI-enabled devices. ARK projects these will grow from ~10% of approvals today to ~30% by 2030.
• Drug Discovery: Traditional drug development takes over a decade and costs billions, with an 80% failure rate. AI-driven development can reduce time-to-market by ~40% and total costs by ~4-fold.
• Economic Impact: By truncating time and cost, AI-developed drugs can generate ~$3 billion in cumulative cash flow before a traditional drug reaches break-even, significantly increasing the value of early-stage assets.

3. The Shift to Functional Cures

ARK highlights a transition from chronic symptom management to one-time curative therapies.

• Pricing Model: Because cures deliver value upfront, they command higher prices. For rare diseases, a cure may exceed $1 million per patient—roughly 15 times the lifetime cost of chronic management.
• Case Study (HAE): Hereditary Angioedema (HAE) currently costs $10–$20 million per patient over a lifetime. A one-time gene-editing therapy could replace this, offering superior outcomes.
• Cardiovascular Application: Gene editing is moving into common diseases. A one-time therapy to lower lipids in the 17 million Americans with atherosclerotic cardiovascular disease represents a Total Addressable Market (TAM) of approximately $2.8 trillion.

4. Longevity as a Biological Target

Longevity is framed as a tractable scientific target rather than a speculative endeavor, focusing on the gradual dysregulation of cellular processes.

• Measurement Evolution: Aging measurement has progressed from basic clinical markers (blood pressure) to functional performance (grip strength) and now to molecular clocks (DNA methylation and proteomics).
• Economic Potential: Using a QALY framework, ARK estimates the US longevity opportunity at $1.2 quadrillion. This is based on the potential to add 11.9 billion healthy life years to the US population, valued at $100,000 per QALY.

5. Synthesis and Conclusion

The convergence of multiomics, AI, and robotics is creating a new paradigm in healthcare. The "Multiomix AI Flywheel" is not just improving existing processes but is fundamentally changing the economic value of medical intervention. By shifting from chronic care to functional cures and treating aging as a measurable biological process, the industry is moving toward a future where the economic value of health is measured in quadrillions, driven by the ability to durably repair the underlying mechanisms of disease.